Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 499-504

  Rossi, Gemma Caterina Maria ^a   Pasinetti, Gian Maria ^b   Scudeller, Luigia ^a   Tinelli, Carmine ^a   Milano, Giovanni ^a   Bianchi, Paolo Emilio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UO Oculistica   (Italy)

Author keywords

Adherence; Glaucoma; Travatan dosing aid; Travoprost; Travoprost timolol fixed combination

Indexed keywords

TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; SELF REPORT; SEX DIFFERENCE; SYSTEMIC THERAPY; TREATMENT DURATION;

AGED; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TIMOLOL; TREATMENT OUTCOME;

EID: 77249148998     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003601994     Document Type: Article

References (29)

1. Coleman AL. Glaucoma. Lancet 1999;354:1803-10
2. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
3. Leske MC, Heijl A, Hussein M, et al.; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
4. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6
5. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and primary open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134
6. Kass MA. Compliance and prognosis in glaucoma [editorial]. Arch Ophthalmol 1985;103:504
7. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90
8. Friedman DS, Jampel HD, Congdom NG, et al. The Travatan Dosing Aid accurately records when drops taken. Am J Ophthalmol 2007;143:699-701
9. Flowers B, Wand M, Piltz-Seymour J, et al. Patients' and physicians' perception of the Travoprost Dosing Aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open angle glaucoma or ocular hypertension. Clin Ther 2006;28:1803-11
10. Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. J Glaucoma 2006;15:40-6
11. Cronin TH, Kahook MY, Lathrop KL, Noecker RJ. Accuracy and performance of a commercially available Dosing Aid. Br J Ophthalmol 2007;91:497-9
12. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 2009;116:191-9
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
14. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986;101:524-30
15. Weinreb RN, Khaw PT. Primary open angle glaucoma. Lancet 2004;363:1711-20
16. Jampel HD, Schwartz GF, Robin AL, Abrams DA. Patient preferences for eye drop characteristics. A willingness to pay analysis. Arch Ophthalmol 2003;121:540-6
17. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002;18:401-9
18. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
19. Sleath B, Robin AL, Covert D, et al. Patient-reported behaviour and problems in using glaucoma medications. Ophthalmology 2006;113:431-6
20. Vriesendorp R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol 2007;63:1115-21
21. De Amici D, Klersy C, Ramaioli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anaesthesia. Control Clin Trials 2000;21:103-14
22. Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 2009;116:1097-105
23. Dunker S, Schmucker A, Maier H, Latanoprost/Timolol Fixed Combination Study Group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther 2007;24:376-86
24. Go·i FJ, Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90
25. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
26. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related belief, and adherence in glaucoma. J Glaucoma 2008;115:1320-7
27. Day DG, Sharpe ED, Atkinson MJ, et al. the clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye 2006;20:583-90
28. Muir KW, Santiago-Turla C, Stinnett SS, et al. Health literacy and adherence to glaucoma therapy. Am J Ophthalmol 2006;142:223-6
29. Juzych MS, Randhawa S, Shukairy A, et al. Functional health literacy in patients with glaucoma in urban setting. Arch Ophthalmol 2008;126:718-24